US president Donald Trump has set a countdown for tariffs on imported generic medicines, ending an exemption that had shielded the copycat drugs supplying the bulk of US prescriptions. Announcing the ...

President Donald Trump announced on July 21 that generic drugs imported to the US will face a 100% tariff for one year starting in August 2028 and 200% thereafter. The shares of all generic drug ...

More than a supply chain issue and missing the first mover status, Semaglutide episode has rather exposed systemic chinks and could prove costly for India’s pharmaceutical industry, which supplies ...

Glenmark Pharmaceuticals (BSE: 532296) has launched a US generic version of Zyprexa (olanzapine) for injection, adding another hospital medicine to its growing injectables portfolio as the company ...

Sandoz said the U.S. Food and Drug Administration accepted for review two applications for generic versions of Eli Lilly's Zepbound and Mounjaro, its popular shots for obesity and diabetes. The Swiss ...

The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

The Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 represents a revived effort from the 118th Congress. The Politico report, which pointed out that the measure appears to be aimed ...

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

Monday's heat could fuel storms by 5 p.m., bringing damaging winds, lightning and torrential rain that may impact the evening commute. by LISA FLETCHER, ANDREA NEJMAN, BILL CASTLE & NATHAN AARON For ...

After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production ...